Shapiro GI - Search Results

1

Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.

Johnson N, Bentley J, Wang LZ, Newell DR, Robson CN, Shapiro GI, Curtin NJ. Johnson N, et al. Among authors: shapiro gi. Br J Cancer. 2010 Jan 19;102(2):342-50. doi: 10.1038/sj.bjc.6605479. Epub 2009 Dec 15. Br J Cancer. 2010. PMID: 20010939 Free PMC article.

2

Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.

Jiang J, Matranga CB, Cai D, Latham VM Jr, Zhang X, Lowell AM, Martelli F, Shapiro GI. Jiang J, et al. Among authors: shapiro gi. Cancer Res. 2003 Nov 1;63(21):7410-22. Cancer Res. 2003. PMID: 14612540

3

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.

Shapiro GI. Shapiro GI. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4270s-4275s. doi: 10.1158/1078-0432.CCR-040020. Clin Cancer Res. 2004. PMID: 15217973 Review.

4

AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.

Cai D, Byth KF, Shapiro GI. Cai D, et al. Among authors: shapiro gi. Cancer Res. 2006 Jan 1;66(1):435-44. doi: 10.1158/0008-5472.CAN-05-1769. Cancer Res. 2006. PMID: 16397259

5

Cyclin-dependent kinase pathways as targets for cancer treatment.

Shapiro GI. Shapiro GI. J Clin Oncol. 2006 Apr 10;24(11):1770-83. doi: 10.1200/JCO.2005.03.7689. J Clin Oncol. 2006. PMID: 16603719 Review.

6

The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.

Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. Gizatullin F, et al. Among authors: shapiro gi. Cancer Res. 2006 Aug 1;66(15):7668-77. doi: 10.1158/0008-5472.CAN-05-3353. Cancer Res. 2006. PMID: 16885368

7

Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.

Cai D, Latham VM Jr, Zhang X, Shapiro GI. Cai D, et al. Among authors: shapiro gi. Cancer Res. 2006 Sep 15;66(18):9270-80. doi: 10.1158/0008-5472.CAN-06-1758. Cancer Res. 2006. PMID: 16982772

8

Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage.

Johnson N, Cai D, Kennedy RD, Pathania S, Arora M, Li YC, D'Andrea AD, Parvin JD, Shapiro GI. Johnson N, et al. Among authors: shapiro gi. Mol Cell. 2009 Aug 14;35(3):327-39. doi: 10.1016/j.molcel.2009.06.036. Mol Cell. 2009. PMID: 19683496 Free PMC article.

9

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JHM, Shapiro GI. Boss DS, et al. Among authors: shapiro gi. Ann Oncol. 2010 Apr;21(4):884-894. doi: 10.1093/annonc/mdp377. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825886 Free PMC article. Clinical Trial.

10

Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.

Johnson N, Shapiro GI. Johnson N, et al. Among authors: shapiro gi. Expert Opin Ther Targets. 2010 Nov;14(11):1199-212. doi: 10.1517/14728222.2010.525221. Expert Opin Ther Targets. 2010. PMID: 20932174 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters